Glioma and glioblastoma ‑ how much do we (not) know? (Review)

Jovčevska,Ivana; Kočevar,Nina; Komel,Radovan

doi:10.3892/mco.2013.172

Glioma and glioblastoma ‑ how much do we (not) know? (Review)

Authors:
- Ivana Jovčevska
- Nina Kočevar
- Radovan Komel
View Affiliations

Affiliations: Medical Center for Molecular Biology, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana 1000, Slovenia
Published online on: August 26, 2013 https://doi.org/10.3892/mco.2013.172
Pages: 935-941

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer is a heterogeneous disease, which provides a broad field for investigation, while simultaneously reducing the chances for a universal treatment. Malignant gliomas are the most common type of primary brain tumors. The heterogeneity of gliomas regarding clinical presentation, pathology and response to treatment makes this type of tumor a challenging area of research. As the clinical symptoms may be unspecific (e.g., seizures and headaches) it is often difficult to diagnose a patient in the early stages of the disease. Thus far, there are no known genetic patterns of inheritance of this disease. Currently, the treatment of glioblastoma involves surgery, whenever possible, followed by radiation and chemotherapy. Experimental procedures, such as passive and active immunotherapy, use of angiogenesis inhibitors in combination with chemotherapeutics and gene/antibody therapy, are additional treatment options. However, as the brain is difficult to access due to the presence of the blood‑brain barrier (BBB), none of the above‑mentioned therapies have been successful in curing this disease. The lack of knowledge regarding the mechanisms underlying the development and progression of gliomas further adds to the difficulties. Currently, investigations are focused on the development of novel methods for improving the outcome of this disease. however, despite the extensive investigations, 88% of all glioblastoma multiforme (GBM) patients succumb to the disease within 3 years. GBM remains one of the most challenging malignancies worldwide.

View Figures

View References

1.	Bhatt AN, Mathur R, Farooque A, Verma A and Dwarakanath BS: Cancer biomarkers - current perspectives. Indian J Med Res. 132:129–149. 2010.PubMed/NCBI
2.	Cho WC: Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer. 6:252007. View Article : Google Scholar : PubMed/NCBI
3.	Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
5.	Bailey P and Cushing H: A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis. JB Lippincott & Co.; Philadelphia, PA: 1926
6.	Galon J, Pages F, Marincola FM, et al: Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 10:2052012. View Article : Google Scholar : PubMed/NCBI
7.	Louis DN, Holland EC and Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol. 159:779–786. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Okada H, Kohanbash G, Zhu X, et al: Immunotherapeutic approaches for glioma. Crit Rev Immunol. 29:1–42. 2009. View Article : Google Scholar
9.	Iacob G and Dinca EB: Current data and strategy in glioblastoma multiforme. J Med Life. 2:386–393. 2009.PubMed/NCBI
10.	Bralten LB and French PJ: Genetic alterations in glioma. Cancers. 3:1129–1140. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Yoshida J: Molecular neurosurgery using gene therapy to treat malignant glioma. Nagoya J Med Sci. 59:97–105. 1996.PubMed/NCBI
12.	Li J, Di C, Mattox AK, Wu L and Adamson DC: The future role of personalized medicine in the treatment of glioblastoma multiforme. Pharmgenomics Pers Med. 3:111–127. 2010.PubMed/NCBI
13.	Chi A and Komaki R: Treatment of brain metastasis from lung cancer. Cancers. 2:2100–2137. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Mathieu D, Kondziolka D, Cooper PB, et al: Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg. 54:241–247. 2007.PubMed/NCBI
15.	Daga A, Bottino C, Castriconi R, Gangemi R and Ferrini S: New perspectives in glioma immunotherapy. Curr Pharm Des. 17:2439–2467. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Ali SA, McHayleh WM, Ahmad A, et al: Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg. 109:268–272. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Farrell CJ and Plotkin SR: Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin. 25:925–946. viii2007. View Article : Google Scholar : PubMed/NCBI
18.	Fisher JL, Schwartzbaum JA, Wrensch M and Wiemels JL: Epidemiology of brain tumors. Neurol Clin. 25:867–890. vii2007. View Article : Google Scholar : PubMed/NCBI
19.	Chen J, Li Y, Yu TS, et al: A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 488:522–526. 2012. View Article : Google Scholar : PubMed/NCBI
20.	Westermark B: Glioblastoma - a moving target. Ups J Med Sci. 117:251–256. 2012. View Article : Google Scholar : PubMed/NCBI
21.	Van Gool S, Maes W, Ardon H, Verschuere T, Van Cauter S and De Vleeschouwer S: Dendritic cell therapy of high-grade gliomas. Brain Pathol. 19:694–712. 2009.PubMed/NCBI
22.	Gruber ML and Buster WP: Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol. 27:33–38. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Pluchino S, Zanotti L, Deleidi M and Martino G: Neural stem cells and their use as therapeutic tool in neurological disorders. Brain Res Brain Res Rev. 48:211–219. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Goldman S: Glia as neural progenitor cells. Trends Neurosci. 26:590–596. 2003. View Article : Google Scholar : PubMed/NCBI
25.	Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA and Lemischka IR: A stem cell molecular signature. Science. 298:601–604. 2002. View Article : Google Scholar : PubMed/NCBI
26.	Hadnagy A, Gaboury L, Beaulieu R and Balicki D: SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 312:3701–3710. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821–5828. 2003.PubMed/NCBI
28.	Altman J: Autoradiographic and histological studies of postnatal neurogenesis. 3. Dating the time of production and onset of differentiation of cerebellar microneurons in rats. J Comp Neurol. 136:269–293. 1969. View Article : Google Scholar : PubMed/NCBI
29.	Corotto FS, Henegar JA and Maruniak JA: Neurogenesis persists in the subependymal layer of the adult mouse brain. Neurosci Lett. 149:111–114. 1993. View Article : Google Scholar : PubMed/NCBI
30.	Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al: Neurogenesis in the adult human hippocampus. Nat Med. 4:1313–1317. 1998. View Article : Google Scholar : PubMed/NCBI
31.	Baylin SB and Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
32.	Jaenisch R and Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 33(Suppl): 245–254. 2003. View Article : Google Scholar : PubMed/NCBI
33.	Driessens G, Beck B, Caauwe A, Simons BD and Blanpain C: Defining the mode of tumour growth by clonal analysis. Nature. 488:527–530. 2012. View Article : Google Scholar : PubMed/NCBI
34.	Vermeulen L, Sprick MR, Kemper K, Stassi G and Medema JP: Cancer stem cells - old concepts, new insights. Cell Death Differ. 15:947–958. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Gilbertson RJ and Graham TA: Cancer: Resolving the stem-cell debate. Nature. 488:462–463. 2012. View Article : Google Scholar : PubMed/NCBI
36.	Ailles LE and Weissman IL: Cancer stem cells in solid tumors. Curr Opin Biotechnol. 18:460–466. 2007. View Article : Google Scholar : PubMed/NCBI
37.	Welte Y, Adjaye J, Lehrach HR and Regenbrecht CR: Cancer stem cells in solid tumors: elusive or illusive? Cell Commun Signal. 8:62010. View Article : Google Scholar : PubMed/NCBI
38.	Makino S: The role of tumor stem-cells in regrowth of the tumor following drastic applications. Acta Unio Int Contra Cancrum. 15(Suppl 1): 196–198. 1959.PubMed/NCBI
39.	Jordan CT, Guzman ML and Noble M: Cancer stem cells. N Engl J Med. 355:1253–1261. 2006. View Article : Google Scholar : PubMed/NCBI
40.	Liu G, Yuan X, Zeng Z, et al: Analysis of gene expression and chemoresistance of CD133⁺ cancer stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
41.	Albini A and Sporn MB: The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 7:139–147. 2007. View Article : Google Scholar : PubMed/NCBI
42.	Calabrese C, Poppleton H, Kocak M, et al: A perivascular niche for brain tumor stem cells. Cancer Cell. 11:69–82. 2007. View Article : Google Scholar : PubMed/NCBI
43.	Crea F, Danesi R and Farrar WL: Cancer stem cell epigenetics and chemoresistance. Epigenomics. 1:63–79. 2009. View Article : Google Scholar
44.	Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC: Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 183:1797–1806. 1996. View Article : Google Scholar : PubMed/NCBI
45.	Hirschmann-Jax C, Foster AE, Wulf GG, et al: A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 101:14228–14233. 2004.
46.	Martin CM, Meeson AP, Robertson SM, et al: Persistent expression of the ATP-binding cassette transporter, Abcg2, identifies cardiac SP cells in the developing and adult heart. Dev Biol. 265:262–275. 2004. View Article : Google Scholar : PubMed/NCBI
47.	Shimano K, Satake M, Okaya A, et al: Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am J Pathol. 163:3–9. 2003. View Article : Google Scholar : PubMed/NCBI
48.	Umemoto T, Yamato M, Nishida K, Yang J, Tano Y and Okano T: Limbal epithelial side-population cells have stem cell-like properties, including quiescent state. Stem Cells. 24:86–94. 2006. View Article : Google Scholar : PubMed/NCBI
49.	Yano S, Ito Y, Fujimoto M, Hamazaki TS, Tamaki K and Okochi H: Characterization and localization of side population cells in mouse skin. Stem Cells. 23:834–841. 2005. View Article : Google Scholar : PubMed/NCBI
50.	Ribou AC, Vigo J, Kohen E and Salmon JM: Microfluorometric study of oxygen dependence of (1″-pyrene butyl)-2-rhodamine ester probe in mitochondria of living cells. J Photochem Photobiol B. 70:107–115. 2003.PubMed/NCBI
51.	Liu WH, Qian NS, Li R and Dou KF: Replacing Hoechst33342 with rhodamine123 in isolation of cancer stem-like cells from the MHCC97 cell line. Toxicol In Vitro. 24:538–545. 2010. View Article : Google Scholar : PubMed/NCBI
52.	Pfenninger CV, Roschupkina T, Hertwig F, et al: CD133 is not present on neurogenic astrocytes in the adult subventricular zone, but on embryonic neural stem cells, ependymal cells, and glioblastoma cells. Cancer Res. 67:5727–5736. 2007. View Article : Google Scholar : PubMed/NCBI
53.	Ieta K, Tanaka F, Haraguchi N, et al: Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol. 15:638–648. 2008. View Article : Google Scholar : PubMed/NCBI
54.	Monzani E, Facchetti F, Galmozzi E, et al: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer. 43:935–946. 2007. View Article : Google Scholar : PubMed/NCBI
55.	Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature. 432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
56.	Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 90:5002–5012. 1997.PubMed/NCBI
57.	Miraglia S, Godfrey W, Yin AH, et al: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 90:5013–5021. 1997.PubMed/NCBI
58.	Mizrak D, Brittan M and Alison M: CD133: molecule of the moment. J Pathol. 214:3–9. 2008. View Article : Google Scholar : PubMed/NCBI
59.	Florek M, Haase M, Marzesco AM, et al: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 319:15–26. 2005. View Article : Google Scholar : PubMed/NCBI
60.	Weigmann A, Corbeil D, Hellwig A and Huttner WB: Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA. 94:12425–12430. 1997. View Article : Google Scholar
61.	Shmelkov SV, Jun L, St Clair R, et al: Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood. 103:2055–2061. 2004. View Article : Google Scholar : PubMed/NCBI
62.	Bao S, Wu Q, McLendon RE, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
63.	Yamanaka R: Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med. 14:228–235. 2008. View Article : Google Scholar : PubMed/NCBI
64.	Bulik M, Jancalek R, Vanicek J, Skoch A and Mechl M: Potential of MR spectroscopy for assessment of glioma grading. Clin Neurol Neurosurg. 115:146–153. 2013. View Article : Google Scholar : PubMed/NCBI
65.	Komoroski RA, Heimberg C, Cardwell D and Karson CN: Effects of gender and region on proton MRS of normal human brain. Magn Reson Imaging. 17:427–433. 1999. View Article : Google Scholar : PubMed/NCBI
66.	Li BS, Wang H and Gonen O: Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. Magn Reson Imaging. 21:923–928. 2003. View Article : Google Scholar : PubMed/NCBI
67.	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
68.	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
69.	Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
70.	Wang Q, Li P, Li A, et al: Plasma specific miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 31:972012. View Article : Google Scholar : PubMed/NCBI
71.	Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
72.	Grossman R, Rudek MA, Brastianos H, et al: The impact of bevacizumab on temozolomide concentrations in intracranial U87 gliomas. Cancer Chemother Pharmacol. 70:129–139. 2012. View Article : Google Scholar : PubMed/NCBI
73.	Walker MD, Alexander E Jr, Hunt WE, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 49:333–343. 1978. View Article : Google Scholar : PubMed/NCBI
74.	Reardon DA, Quinn JA, Rich JN, et al: Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 104:1478–1486. 2005. View Article : Google Scholar : PubMed/NCBI
75.	Abbott NJ, Ronnback L and Hansson E: Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 7:41–53. 2006. View Article : Google Scholar : PubMed/NCBI
76.	Anderson CM and Nedergaard M: Astrocyte-mediated control of cerebral microcirculation. Trends Neurosci. 26:340–345. 2003. View Article : Google Scholar : PubMed/NCBI
77.	Nedergaard M, Ransom B and Goldman SA: New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci. 26:523–530. 2003. View Article : Google Scholar : PubMed/NCBI
78.	Pardridge WM: Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 3:90–105. 512003. View Article : Google Scholar : PubMed/NCBI
79.	Abbott NJ: Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int. 45:545–552. 2004. View Article : Google Scholar : PubMed/NCBI
80.	Cserr HF and Bundgaard M: Blood-brain interfaces in vertebrates: a comparative approach. Am J Physiol. 246:R277–R288. 1984.PubMed/NCBI
81.	Hickey MJ, Malone CC, Erickson KL, et al: Cellular and vaccine therapeutic approaches for gliomas. J Transl Med. 8:1002010. View Article : Google Scholar : PubMed/NCBI
82.	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
83.	Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 70:779–787. 2008. View Article : Google Scholar : PubMed/NCBI
84.	Afanasieva TA, Wittmer M, Vitaliti A, Ajmo M, Neri D and Klemenz R: Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for anti-angiogenic gene therapy. Gene Ther. 10:1850–1859. 2003. View Article : Google Scholar
85.	Sanz L, Blanco B and Alvarez-Vallina L: Antibodies and gene therapy: teaching old ‘magic bullets’ new tricks. Trends Immunol. 25:85–91. 2004.
86.	Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
87.	Vredenburgh JJ, Desjardins A, Herndon JE II, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 13:1253–1259. 2007. View Article : Google Scholar : PubMed/NCBI
88.	Vredenburgh JJ, Desjardins A, Herndon JE II, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 25:4722–4729. 2007. View Article : Google Scholar : PubMed/NCBI
89.	Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
90.	Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 22:2184–2191. 2004. View Article : Google Scholar
91.	Friedman HS, Petros WP, Friedman AH, et al: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 17:1516–1525. 1999.PubMed/NCBI
92.	Prados MD, Lamborn K, Yung WK, et al: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 8:189–193. 2006. View Article : Google Scholar
93.	Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 7:3692005.
94.	Pope WB, Lai A, Nghiemphu P, Mischel P and Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 66:1258–1260. 2006. View Article : Google Scholar : PubMed/NCBI
95.	Narayana A, Kelly P, Golfinos J, et al: Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 110:173–180. 2009. View Article : Google Scholar : PubMed/NCBI
96.	Mountain A: Gene therapy: the first decade. Trends Biotechnol. 18:119–128. 2000. View Article : Google Scholar
97.	Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 1:118–129. 2001. View Article : Google Scholar : PubMed/NCBI
98.	Segal DM, Weiner GJ and Weiner LM: Bispecific antibodies in cancer therapy. Curr Opin Immunol. 11:558–562. 1999. View Article : Google Scholar : PubMed/NCBI
99.	Hudson PJ: Recombinant antibody constructs in cancer therapy. Curr Opin Immunol. 11:548–557. 1999. View Article : Google Scholar : PubMed/NCBI
100.	Cortez-Retamozo V, Backmann N, Senter PD, et al: Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 64:2853–2857. 2004. View Article : Google Scholar : PubMed/NCBI
101.	Vu KB, Ghahroudi MA, Wyns L and Muyldermans S: Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol. 34:1121–1131. 1997. View Article : Google Scholar : PubMed/NCBI
102.	Song E, Zhu P, Lee SK, et al: Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol. 23:709–717. 2005. View Article : Google Scholar : PubMed/NCBI
103.	Sioud M: Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization. J Mol Biol. 348:1079–1090. 2005. View Article : Google Scholar